Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008

References

• Kim R Emi M Tanabe K Cancer immunoediting from immune surveillance to immune escape Immunology 2007 121 1 1 14 17386080
   PubMed Web of Science ®Google Scholar
• Bilusic M Gulley JL Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines Cancer Immunol Immunother 2012 61 1 109 117 22120693
   PubMed Web of Science ®Google Scholar
• Bilusic M Madan RA Therapeutic cancer vaccines: the latest advancement in targeted therapy Am J Ther 2012 19 6 e172 e181 21317622
   PubMedGoogle Scholar
• Klebanoff CA Acquavella N Yu Z Restifo NP Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011 239 1 27 44 21198663
   PubMed Web of Science ®Google Scholar
• Topalian SL Hodi FS Brahmer JR Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 2012 366 26 2443 2454 22658127
   PubMed Web of Science ®Google Scholar
• Hodi FS O’Day SJ McDermott DF Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 2010 363 8 711 723 20525992
   PubMed Web of Science ®Google Scholar
• Feig C Jones JO Kraman M Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer Proc Natl Acad Sci U S A 2013 110 50 20212 20217 24277834
   PubMed Web of Science ®Google Scholar
• Janowitz T Welsh SJ Zaki K Mulders P Eisen T Adjuvant therapy in renal cell carcinoma-past, present, and future Semin Oncol 2013 40 4 482 491 23972712
   PubMed Web of Science ®Google Scholar
• Hoos A Evolution of end points for cancer immunotherapy trials Ann Oncol 2012 23 Suppl 8(Suppl 8) viii47 viii52 22918928
   PubMed Web of Science ®Google Scholar
• Andersen BM Ohlfest JR Increasing the efficacy of tumor cell vaccines by enhancing cross priming Cancer Lett 2012 325 2 155 164 22809568
   PubMed Web of Science ®Google Scholar
• Schlom J Therapeutic cancer vaccines: current status and moving forward J Natl Cancer Inst 2012 104 8 599 613 22395641
   PubMed Web of Science ®Google Scholar
• Balwit JM Hwu P Urba WJ Marincola FM The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program J Transl Med 2011 9 18 21281484
   PubMed Web of Science ®Google Scholar
• Butt AQ Mills KH Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines Oncogene Epub 10 21 2013
   Web of Science ®Google Scholar
• Drake CG Lipson EJ Brahmer JR Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer Nat Rev Clin Oncol 2014 11 1 24 37 24247168
   PubMed Web of Science ®Google Scholar
• Riley JL Combination checkpoint blockade – taking melanoma immunotherapy to the next level N Engl J Med 2013 369 2 187 189 23724866
   PubMed Web of Science ®Google Scholar
• Koos D Josephs SF Alexandrescu DT Tumor vaccines in 2010: need for integration Cell Immunol 2010 263 2 138 147 20434139
   PubMed Web of Science ®Google Scholar
• Nakano O Sato M Naito Y Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity Cancer Res 2001 61 13 5132 5136 11431351
   PubMed Web of Science ®Google Scholar
• Dougan M Dranoff G Immune therapy for cancer Annu Rev Immunol 2009 27 83 117 19007331
   PubMed Web of Science ®Google Scholar
• Marzbani E Inatsuka C Lu H Disis ML The invisible arm of immunity in common cancer chemoprevention agents Cancer Prev Res (Phila) 2013 6 8 764 773 23918793
   PubMed Web of Science ®Google Scholar
• Kalialis LV Drzewiecki KT Klyver H Spontaneous regression of metastases from melanoma: review of the literature Melanoma Res 2009 19 5 275 282 19633580
   PubMed Web of Science ®Google Scholar
• Liu MA Cancer vaccines Philos Trans R Soc Lond B Biol Sci 2011 366 1579 2823 2826 21893546
   PubMed Web of Science ®Google Scholar
• Clemente CG Mihm MCJr Bufalino R Zurrida S Collini P Cascinelli N Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma Cancer 1996 77 7 1303 1310 8608507
   PubMed Web of Science ®Google Scholar
• Gray A Raff AB Chiriva-Internati M Chen SY Kast WM A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev 2008 222 316 327 18364011
   PubMed Web of Science ®Google Scholar
• Sobol RE The rationale for prophylactic cancer vaccines and need for a paradigm shift Cancer Gene Ther 2006 13 8 725 731 16543919
   PubMed Web of Science ®Google Scholar
• Kimura T McKolanis JR Dzubinski LA MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study Cancer Prev Res (Phila) 2013 6 1 18 26 23248097
   PubMed Web of Science ®Google Scholar
• Finn OJ Cancer vaccines: between the idea and the reality Nat Rev Immunol 2003 3 8 630 641 12974478
   PubMed Web of Science ®Google Scholar
• Hoos A Eggermont AM Janetzki S Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 2010 102 18 1388 1397 20826737
   PubMed Web of Science ®Google Scholar
• Begg CB Justifying the choice of endpoints for clinical trials J Natl Cancer Inst 2013 105 21 1594 1595 24108810
   PubMedGoogle Scholar
• von Elm E Altman DG Egger M Strobe Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Lancet 2007 370 9596 1453 1457 18064739
   PubMed Web of Science ®Google Scholar
• Li LM Menon DK Janowitz T Cross-sectional analysis of data from the US clinical trials database reveals poor translational clinical trial effort for traumatic brain injury, compared with stroke PLoS One 2014 9 1 e84336 24416218
   PubMed Web of Science ®Google Scholar
• Janowitz T Biopharmaceuticals and monoclonal antibodies in oncology trials – a cross-sectional analysis Protein Eng Des Sel 2011 24 1–2 105 111 21037277
   PubMed Web of Science ®Google Scholar
• Zarin D Newsmaker interview: Debora Zarin. Unseen world of clinical trials emerges from US database. Interview by Eliot Marshall Science 2011 333 6039 145 21737714
   PubMed Web of Science ®Google Scholar
• Inrig JK Califf RM Tasneem A The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov Am J Kidney Dis 2014 63 5 771 780 24315119
   PubMed Web of Science ®Google Scholar
• Hirsch BR Califf RM Cheng SK Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov JAMA Intern Med 2013 173 11 972 979 23699837
   PubMed Web of Science ®Google Scholar
• Califf RM Zarin DA Kramer JM Sherman RE Aberle LH Tasneem A Characteristics of clinical trials registered in ClinicalTrials. gov, 2007–2010 JAMA 2012 307 17 1838 1847 22550198
   PubMed Web of Science ®Google Scholar
• Faries MB Hsueh EC Ye X Hoban M Morton DL Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine Clin Cancer Res 2009 15 22 7029 7035 19903777
   PubMed Web of Science ®Google Scholar
• Dayoub EJ Davis MM Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival Hum Vaccin 2011 7 11 1124 1129 22048113
   PubMed Web of Science ®Google Scholar
• Buonaguro L Petrizzo A Tagliamonte M Tornesello ML Buonaguro FM Challenges in cancer vaccine development for hepatocellular carcinoma J Hepatol 2013 59 4 897 903 23714157
   PubMed Web of Science ®Google Scholar
• Russ AJ Wentworth L Xu K Suppression of T-cell expansion by melanoma is exerted on resting cells Ann Surg Oncol 2011 18 13 3848 3857 21465311
   PubMed Web of Science ®Google Scholar
• von Mehren M Arlen P Gulley J The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma Clin Cancer Res 2001 7 5 1181 1191 11350882
   PubMed Web of Science ®Google Scholar
• Wolchok JD Hoos A O’Day S Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin Cancer Res 2009 15 23 7412 7420 19934295
   PubMed Web of Science ®Google Scholar